Group items tagged

SLIDEBOOM PRESENTATION - NORTON SCIENTIFIC LATEST COVERAGE - ZIMBIO - Norton: Donald Roberts, "Scientific Fraud", and DDT By isabelhawthorne on October 17, 2011 http://oneclick.indiatimes.com/article/05ZvgVk22C0Pb?q=Guatemala In http://www.aei.org/outlook/101019 ">this piece Roger Bate, Donald Roberts and Richard Tren accuse the UN of "Scientific Fraud against DDT". Their Accusation is based on an Opinion paper by http://www.dovepress.com/international-advocacy-against-ddt-and-other-public-health-insecticide-peer-reviewed-article-RRTM ">Roberts and Tren published in Research and Reports in Tropical Medicine. So let's look at their paper and see...Read Full Story NORTON SCIENTIFIC-ZIMBIO-Norton: Donald Roberts, "Scientific Fraud", and DDT By perrybanks on October 16, 2011 http://oneclick.indiatimes.com/article/05ZvgVk22C0Pb?q=Guatemala In http://www.aei.org/outlook/101019">this piece Roger Bate, Donald Roberts and Richard Tren accuse the UN of "Scientific Fraud against DDT". Their Accusation is based on an Opinion paper byhttp://www.dovepress.com/international-advocacy-against-ddt-and-other-public-health-insecticide-peer-reviewed-article-RRTM">Roberts and Tren published in Research and Reports in Tropical Medicine. So let's look at their paper and see where...Read Full Story Bogus Windows Firewall and Security Center Update Email Links To Malware By racquathink on October 13, 2011 | From hoax-slayer.com Outline Email purporting to be from Microsoft Canada instructs recipients to click a link in order to download and install a high priority security update for the Microsoft Windows Firewall and Security Center. Brief Analysis The email is not from Microsoft and the link does not point to a security update. Instead, following the instructions in the message will download and install malware. Microsoft will never send security updates via an email. Detailed analysis and references below...Read Full Story Fraud Prevention | NORTON SCIENTIFIC PLANNING APPLICATION - W

SLIDEBOOM PRESENTATION - NORTON SCIENTIFIC LATEST COVERAGE - ZIMBIO - Norton: Donald Roberts, "Scientific Fraud", and DDT By isabelhawthorne on October 17, 2011 http://oneclick.indiatimes.com/article/05ZvgVk22C0Pb?q=Guatemala In http://www.aei.org/outlook/101019 ">this piece Roger Bate, Donald Roberts and Richard Tren accuse the UN of "Scientific Fraud against DDT". Their Accusation is based on an Opinion paper by http://www.dovepress.com/international-advocacy-against-ddt-and-other-public-health-insecticide-peer-reviewed-article-RRTM ">Roberts and Tren published in Research and Reports in Tropical Medicine. So let's look at their paper and see...Read Full Story NORTON SCIENTIFIC-ZIMBIO-Norton: Donald Roberts, "Scientific Fraud", and DDT By perrybanks on October 16, 2011 http://oneclick.indiatimes.com/article/05ZvgVk22C0Pb?q=Guatemala In http://www.aei.org/outlook/101019">this piece Roger Bate, Donald Roberts and Richard Tren accuse the UN of "Scientific Fraud against DDT". Their Accusation is based on an Opinion paper byhttp://www.dovepress.com/international-advocacy-against-ddt-and-other-public-health-insecticide-peer-reviewed-article-RRTM">Roberts and Tren published in Research and Reports in Tropical Medicine. So let's look at their paper and see where...Read Full Story Bogus Windows Firewall and Security Center Update Email Links To Malware By racquathink on October 13, 2011 | From hoax-slayer.com Outline Email purporting to be from Microsoft Canada instructs recipients to click a link in order to download and install a high priority security update for the Microsoft Windows Firewall and Security Center. Brief Analysis The email is not from Microsoft and the link does not point to a security update. Instead, following the instructions in the message will download and install malware. Microsoft will never send security updates via an email. Detailed analysis and references below...Read Full Story Fraud Prevention | NORTON SCIENTIFIC PLANNING APPLICATION - W

/Zimbio/ - Invisible Man is a novel written by Ralph Ellison, and the only one that he published during his lifetime (his other novels were published posthumously). It won him the National Book Award in 1953. The novel addresses many of the social and intellectual issues facing African-Americans in the early twentieth century, including black nationalism, the relationship between black identity and Marxism, and the reformist racial policies of Booker T. Washington, as well as issues of individuality and personal identity. In 1998, the Modern Library ranked Invisible Man nineteenth on its list of the 100 best English-language novels of the 20th century. Time magazine included the novel in its TIME 100 Best English-language Novels from 1923 to 2005.[1] Historical background In his introduction to the 30th Anniversary Edition of Invisible Man,[2] Ellison says that he started writing the book in a barn in Waitsfield, Vermont in the summer of 1945 while on sick leave from the Merchant Marine and that the novel continued to preoccupy him in various parts of New York City. In an interview in The Paris Review 1955,[3] Ellison states that the book took five years to complete with one year off for what he termed an "ill-conceived short novel." Invisible Man was published as a whole in 1952; however, copyright dates show the initial publication date as 1947, 1948, indicating that Ellison had published a section of the book prior to full publication. That section was the famous "Battle Royal" scene, which had been shown to Cyril Connolly, the editor of Horizon magazine by Frank Taylor, one of Ellison's early supporters. Ellison states in his National Book Award acceptance speech that he considered the novel's chief significance to be its experimental attitude. Rejecting the idea of social protest-as Ellison would later put it-he did not want to write another protest novel, and also seeing the highly regarded styles of Naturalism and Realism too limiting to speak to the

Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer's disease has failed to show signs of effectiveness in one of the four late-stage tests in patients. "While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer's disease will be gained following the availability of additional data," said Pfizer's head of primary care medicines development. The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad. Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer's disease. Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque. The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease. According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop. The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all. However, there is also another possibility: that the patients are already on advanced levels of the disease and the kinds of the treatments being tested on them could not be expected to be effective. Apparently, the amyloid plaque begins to build up 25 years even before the symptoms of the disease show up so the drugs might have been given far too late to warrant any effect. "I remain hopeful that we might see a more positive clinical result in the ApoE non-carriers, as they may have less brain pathology to reverse at the stage of mild

As one of the leading providers of classic literature commentaries/reviews online, Norton Collection of Classic and Scientific Literature keeps a wide array of titles from prominent to obscure authors of different genres and era. To ensure the you will get utmost quality service from Norton Collection of Classic and Scientific Literature, we constantly update our collection to include newer titles and accomodate requested reviews of users whenever we can. And with so many titles on our archives, it is essential for readers to be able to search something they want quickly. You'll be delighted to know that you can zero in on your target books by giving us the author name, relevant keywords or the title itself - and wait for the results just in seconds! For those who just want to browse around and find other interesting books on their favorite category, Norton Collection of Classic and Scientific Literature has a Bookshelf section. Every title we have comes with complete description and recommendations. SEE MORE DETAILS : norton-scientificcollection.com

Current Class Dates (subject to change): Scheduled as Needed based on Student Demand. Email us atonlinetrain@nortonaudits.com if you are interested in this course. Description - This is an advanced-level class that takes an in-depth examination of severe noncompliance,clinical data fabrication and falsification, scientific misconduct and fraud cases. The course focus is on developing skills for preventing fraud and misconduct and preparing clinical research professionals to better handle severe noncompliance. Class Agenda/Modules - Instructors Make a Difference Defining Clinical Research Fraud and Misconduct Evaluation of Case History R.E.S.E.A.R.C.H. TM Skills Program Advanced Auditing and Monitoring Skills for Prevention Case Development Typical Class Attendee - Sponsor Auditors Contract Research Organization Auditors Clinical Research Associates and Monitors Institutional Review Board Internal Auditors Food and Drug Administration Investigators Independent Consultant Auditors Compliance Auditors Experience Level - Advanced; CRC, CRA or Auditor position for two years, preferably with a four year medical or science degree Class Price - $1500 (10% Southeast Regional Discount and 10% multiple persons from the same organization discounts are available)